Calcium pyrophosphate dihydrate (CPPD) arthritis is a joint disease that can cause attacks of arthritis. Like gout, crystals form in the joints. But in this arthritis, the crystals are not formed from uric acid.
Deposition of calcium pyrophosphate dihydrate (CPPD) causes this form of arthritis. The buildup of this chemical forms crystals in the joints. This leads to attacks of joint swelling and pain in the knees, wrists, ankles, and other joints.
Among older adults, CPPD is a common cause of sudden (acute) arthritis in one joint.
CPPD arthritis mainly affects the elderly because joint degeneration and osteoarthritis increases with age. Such joint damage increases the tendency of CPPD deposition. However, CPPD arthritis can sometimes affect younger people who have conditions such as:
In most cases, CPPD arthritis does not show any symptoms.
Some people with chronic CPPD deposition in large joints may have the following symptoms:
Attacks of joint pain can last for months. There may be no symptoms between attacks.
Because the symptoms are similar, CPPD arthritis can be confused with:
Most arthritic conditions show similar symptoms. Carefully testing the joint fluid for crystals can help the doctor diagnose the condition.
You may undergo the following tests:
Treatment may involve removing fluid to relieve pressure in the joint. A needle is placed into the joint and fluid is removed (aspirated). Some common treatment options are:
Most people do well with treatment to reduce the acute joint pain. A medicine such as colchicine may help prevent repeat attacks. There is no treatment to remove the CPPD crystals.
Permanent joint damage can occur without treatment.
Call your health care provider if you have attacks of joint swelling and joint pain.
There is no known way to prevent this disorder. However, treating other problems that may cause CPPD arthritis may make the condition less severe.
Regular follow-up visits may help prevent permanent damage of the affected joints.
Reviewed By: Gordon A. Starkebaum, MD, Professor of Medicine, Division of Rheumatology, University of Washington School of Medicine, Seattle, WA. Also reviewed by David Zieve, MD, MHA, Isla Ogilvie, PhD, and the A.D.A.M. Editorial team.